Sprycel generic
Sprycel is an anti-cancer drug owned by Bristol Myers Squibb. It's key active ingredient is dasatinib. The drug was first authorised for market use on 28th June, 2006 and is available in tablet form for oral consumption.
When will Sprycel generic be available?
At present, Sprycel is still under patent with the last patent (US7491725) set to expire on 28th September, 2026. This suggests that there will be no generic versions available until after this date, barring any successful Para IV filings.
Sprycel uses
Sprycel contains dasatinib, an active ingredient that is effective in treating certain types of cancer including chronic myelogenous leukemia and acute lymphoblastic leukemia. It works by slowing or stopping the growth of cancer cells. This makes it a highly effective medication for managing these types of cancer.
Sprycel patent expiration
Sprycel currently holds four patents. The most recent patent which is due to expire on 28th September, 2026 is US7491725 titled 'Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors'. For anyone looking into the Sprycel generic release date, more patent details can be found below: